-
Mashup Score: 3
Our data show that KRd plus ASCT showed superiority in terms of improved responses compared with the other two treatment approaches and support the prospective randomised evaluation of KRd plus ASCT versus standards of care (eg, daratumumab plus bortezomib plus thalidomide plus dexamethasone plus ASCT) in transplant-eligible patients with multiple myeloma. Carfilzomib plus lenalidomide as…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Our data show that KRd plus ASCT showed superiority in terms of improved responses compared with the other two treatment approaches and support the prospective randomised evaluation of KRd plus ASCT versus standards of care (eg, daratumumab plus bortezomib plus thalidomide plus dexamethasone plus ASCT) in transplant-eligible patients with multiple myeloma. Carfilzomib plus lenalidomide as…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Online: FORTE trial – #Carfilzomib with #cyclophosphamide and #dexamethasone or #lenalidomide and dexamethasone + ASCT or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance for patients with newly diagnosed #multiplemyeloma https://t.co/HlPP0Ibcyb
-
-
Mashup Score: 3Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation: - 3 year(s) ago
Abstract Background Post-transplant cyclophosphamide (PT-Cy) has become a standard of care in haploidentical hematopoietic stem cell transplantation (HSCT) to reduce the risk of graft-versus-host d…
Source: JACC: CardioOncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Post-transplant #cyclophosphamide is associated with a higher incidence of cardiac events within the first 100 days after allogeneic #BMTsm @RemyDulery @Mohty_EBMT @Razan_Mohty https://t.co/wokFdJzOfv
-
-
Mashup Score: 0Cyclophosphamide plus high-dose glucocorticoids did not confer survival benefit in IPF - 3 year(s) ago
In patients with acute exacerbation of idiopathic pulmonary fibrosis, adding IV cyclophosphamide to high-dose glucocorticoids increased mortality at 3 months, researchers reported at the European Respiratory Society International Congress.“Current guidelines, that have not changed for 10 years, support using high-dose glucocorticoids such as intravenous methylprednisolone pulses. An
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Intravenous #cyclophosphamide in addition to high-dose #glucocorticosteroids increased 3-month mortality in patients with acute exacerbation of #IPF, according to a study presented at #ERScongress https://t.co/h0fNQ8yb0R
-
-
Mashup Score: 0Cyclophosphamide plus high-dose glucocorticoids did not confer survival benefit in IPF - 3 year(s) ago
In patients with acute exacerbation of idiopathic pulmonary fibrosis, adding IV cyclophosphamide to high-dose glucocorticoids increased mortality at 3 months, researchers reported at the European Respiratory Society International Congress.“Current guidelines, that have not changed for 10 years, support using high-dose glucocorticoids such as intravenous methylprednisolone pulses. An
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Intravenous #cyclophosphamide in addition to high-dose #glucocorticosteroids increased 3-month mortality in patients with acute exacerbation of #IPF, according to a study presented at #ERScongress https://t.co/O7FwBJcB5p
-
-
Mashup Score: 0Cyclophosphamide plus high-dose glucocorticoids did not confer survival benefit in IPF - 3 year(s) ago
In patients with acute exacerbation of idiopathic pulmonary fibrosis, adding IV cyclophosphamide to high-dose glucocorticoids increased mortality at 3 months, researchers reported at the European Respiratory Society International Congress.“Current guidelines, that have not changed for 10 years, support using high-dose glucocorticoids such as intravenous methylprednisolone pulses. An
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Intravenous #cyclophosphamide in addition to high-dose #glucocorticosteroids increased 3-month mortality in patients with acute exacerbation of #IPF, according to a study presented at #ERScongress https://t.co/h0fNQ8yb0R
-
-
Mashup Score: 2
Commentary by Dr. Seth Rotz
Source: www.jacc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
🎧 Listen to Dr. @SethRotz discuss early cardiac toxicity associated w/ post-transplant #cyclophosphamide in allogeneic #stemcell transplantation. https://t.co/MuDekSDyZ3 #JACCCardioOnc #JACCPodcast #CardioOnc #MedTwitter https://t.co/olI2xcBhZV
-
-
Mashup Score: 0Mechanisms of hemorrhagic cystitis - 3 year(s) ago
The vast majority of cases of infectious cystitis are easily treated, and most patients have no long-term complications. However, hemorrhagic cystitis is a potentially deadly complication associated with pelvic radiation therapy, chemotherapy, and stem-cell …
Source: PubMed Central (PMC)Categories: Hem/Oncs, Latest HeadlinesTweet-
Mechanism of hemorrhagic cystitis and prevention. https://t.co/rwJ55dYZTL #cyclophosphamide, #ifosfamide, #acrolein, #mesna #HemeOnc_Topic_Review #HemeOnc_Clinical_Pearls #medtwitter #MedEd
-
-
Mashup Score: 3Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation: - 3 year(s) ago
Abstract Background Post-transplant cyclophosphamide (PT-Cy) has become a standard of care in haploidentical hematopoietic stem cell transplantation (HSCT) to reduce the risk of graft-versus-host d…
Source: JACC: CardioOncologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Post-transplant #cyclophosphamide is associated w/ a higher incidence of cardiac events within the first 100 days after allogeneic stem cell transplantation. https://t.co/Wj4igRcHIK #JACCCardioOnc #CardioOnc #GVHD #CVD #CVRF #LVEF #MedTwitter @RemyDulery https://t.co/OTAElakPYB
-
-
Mashup Score: 0JNCCN 360 - MM - Weekly Carfilzomib-Based Regimen in Resistant Myeloma: Phase II Trial - 3 year(s) ago
By: Celeste L. Dixon Posted: Friday, April 23, 2021 The dosing schedule convenience of weekly carfilzomib plus cyclophosphamide and dexamethasone appears to be a bonus on top of its safety and effectiveness as a regimen for patients with relapsed or refractory multiple myeloma, especially for those who are…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase II trial results on weekly #carfilzomib plus #cyclophosphamide and #dexamethasone for resistant #multiplemyeloma: https://t.co/zSWt6KNg0O #MMSM #JNCCN360 https://t.co/oyMCVC5UgD
-
ICYMI: FORTE trial – #Carfilzomib with #cyclophosphamide and #dexamethasone or #lenalidomide and dexamethasone plus ASCT or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance for patients with newly diagnosed #multiplemyeloma https://t.co/HlPP0HTBGD